Journal of Pharmacovigilance

Integration of Pharmacovigilance and Risk Management in Modern Medicine Safety Systems

Helena Kravets^* Department of Clinical Pharmacology, Baltic Medical University, Riga, Latvia
^*Correspondence: Helena Kravets, Department of Clinical Pharmacology, Baltic Medical University, Riga, Latvia, Email:

Received: 10-Feb-2026, Manuscript No. JP-26-31404; Editor assigned: 12-Feb-2026, Pre QC No. JP-26-31404; Reviewed: 26-Feb-2026, QC No. JP-26-31404; Revised: 05-Mar-2026, Manuscript No. JP-26-31404; Published: 12-Mar-2026, DOI: 10.35248/2329-6887.26.14.549

Description

Pharmacovigilance and risk management are closely connected disciplines that work together to ensure the safe use of medicinal products across their entire lifecycle. Pharmacovigilance focuses on the detection, assessment, and prevention of adverse effects, while risk management translates safety findings into structured actions that reduce harm and improve patient outcomes. When combined, these two systems form a continuous cycle of safety monitoring and intervention that supports both regulatory decision-making and clinical practice.

Pharmacovigilance begins with the collection of safety data from multiple sources. These include clinical trials, spontaneous adverse event reports, post-marketing surveillance studies, and published scientific literature. Each source contributes different types of information about how a medicine behaves in real-world conditions. Clinical trials provide controlled environments with limited populations, while post-marketing data reflect broader and more diverse patient experiences. This combination allows for a more complete understanding of a medicine’s safety profile.

Once data is collected, it is analyzed to identify potential safety signals. These signals represent patterns or associations that may indicate a new or previously unrecognized risk. Statistical tools and clinical evaluation are used together to determine whether these signals are meaningful. However, signal identification alone does not confirm a causal relationship; further investigation is always required. This is where risk management processes become essential.

Risk management takes the findings from pharmacovigilance and transforms them into structured strategies aimed at minimizing harm. These strategies may include updates to prescribing information, restrictions on use in certain populations, or additional monitoring requirements. In some cases, educational materials are developed for healthcare professionals and patients to ensure safe and appropriate use of the medicine. These measures are designed based on the severity and likelihood of identified risks.

A central element connecting pharmacovigilance and risk management is the risk management plan. This document outlines known and potential risks associated with a medicinal product and describes how they will be monitored and controlled. It is developed during the regulatory approval process and updated throughout the product’s lifecycle. The plan ensures that safety concerns identified through pharmacovigilance are systematically addressed through practical interventions (1-5).

Regulatory authorities play a key role in overseeing both pharmacovigilance and risk management activities. In Europe, for example, the European Medicines Agency coordinates safety evaluations and ensures that risk management plans are implemented effectively across member states. National agencies also contribute by collecting local safety data and enforcing regulatory requirements. This coordinated approach ensures consistency in safety standards across different regions.

Data management systems are essential for linking pharmacovigilance findings with risk management actions. Large databases such as EudraVigilance allow for the centralized collection and analysis of adverse event reports. These systems enable rapid detection of safety signals and support timely decision-making. Once a potential risk is confirmed, regulatory and industry stakeholders work together to implement appropriate control measures (6-10).

Communication is another critical aspect of integrating pharmacovigilance and risk management. Safety information must be clearly communicated to healthcare professionals, patients, and regulatory bodies. This includes issuing safety alerts, updating product labels, and publishing risk minimization guidelines. Effective communication ensures that safety measures are understood and applied in clinical practice, reducing the likelihood of medication-related harm.

Conclusion

Pharmacovigilance and risk management are interdependent systems that work together to ensure the safe use of medicines. Pharmacovigilance also contributes to the continuous evaluation of risk management effectiveness. After risk minimization measures are implemented, ongoing monitoring is conducted to determine whether they are achieving their intended outcomes. If risks persist or new concerns arise, additional interventions may be introduced. This feedback loop ensures that safety strategies remain relevant and responsive to real-world conditions. Pharmacovigilance provides the evidence base through continuous monitoring and data analysis, while risk management translates this evidence into practical actions that reduce harm. Their integration creates a dynamic safety framework that supports informed decision-making, protects patients, and enhances the overall quality of healthcare.

References

1. Philippidis A. CASGEVY makes history as FDA approves first CRISPR/Cas9 genome edited therapy. Hum Gene Ther. 2024;35(1):1-4.

   [Google Scholar] [Cross ref] [Pub Med]

2. Kanter J, Thompson AA, Pierciey Jr FJ, Hsieh M, Uchida N, Leboulch P, et al. Lovo�cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB�206 study. Am J Hematol. 2023;98(1):11-22.

   [Google Scholar] [Cross ref] [Pub Med]

3. Leonard A, Tisdale JF. A new frontier: FDA approvals for gene therapy in sickle cell disease. Mol Ther. 2024;32(2):264-267.

   [Google Scholar] [Cross ref] [Pub Med]

4. Ye X, Ge M, Tan M, Wu Y, Zhang H, Fu Z. CD19-targeted CAR T therapy treating hematologic malignancies: Hidden danger is the next neighbor to security?. Front Immunol. 2025;16(3):1490491.

   [Google Scholar] [Cross ref] [Pub Med]

5. Shi M, Wang J, Huang H, Liu D, Cheng H, Wang X, et al. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: A phase I/II trial. Nat Commun. 2024;15(4):3371.

   [Google Scholar] [Cross ref] [Pub Med]

6. Fusaroli M, Isgrò V, Cutroneo PM, Ferrajolo C, Cirillo V, Del Bufalo F, et al. Post-marketing surveillance of CAR-T-cell therapies: Analysis of the FDA adverse event reporting system (FAERS) database. Drug Saf. 2022;45(2):891-908.

   [Google Scholar] [Cross ref] [Pub Med]

7. Hoy SM. Delandistrogene Moxeparvovec:First Approval. Drugs. 2023;83(1):1323-1329.

   [Google Scholar] [Cross ref] [Pub Med]

8. Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. ‘Off-the-shelf’allogeneic CAR T cells: Development and challenges. Nat Rev Drug Discov. 2020;19(2):185-199.

   [Google Scholar] [Cross ref] [Pub Med]

9. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch PA, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. science. 2003;302(6):415-419.

   [Google Scholar] [Cross ref] [Pub Med]

10. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008;118(1):4.

    [Google Scholar] [Cross ref] [Pub Med]